| First Author | Tennant KG | Year | 2019 |
| Journal | Diabetes | Volume | 68 |
| Issue | 7 | Pages | 1462-1472 |
| PubMed ID | 31048370 | Mgi Jnum | J:276898 |
| Mgi Id | MGI:6315715 | Doi | 10.2337/db18-1175 |
| Citation | Tennant KG, et al. (2019) Central and Peripheral Administration of Fibroblast Growth Factor 1 Improves Pancreatic Islet Insulin Secretion in Diabetic Mouse Models. Diabetes 68(7):1462-1472 |
| abstractText | Fibroblast growth factor 1 (FGF1) has been shown to reverse hyperglycemia in diabetic rodent models through peripheral and central administration routes. Previous studies demonstrated that insulin is required for central and peripheral FGF1 metabolic improvements; however, it is unknown if FGF1 targets insulin secretion at the islet level. Here we show for the first time that FGF1 increases islet insulin secretion in diabetic mouse models. FGF1 was administered via a single intracerebroventricular or multiple subcutaneous injections to leptin receptor-deficient (db/db), diet-induced obese, and control mice; pancreatic islets were isolated 7 days later for analysis of insulin secretion. Central and peripheral FGF1 significantly lowered blood glucose in vivo and increased ex vivo islet insulin secretion from diabetic, but not control, mice. FGF1 injections to the cisterna magna mimicked intracerebroventricular outcomes, pointing to a novel therapeutic potential. Central effects of FGF1 appeared dependent on reductions in food intake, whereas peripheral FGF1 had acute actions on islet function prior to significant changes in food intake or blood glucose. Additionally, peripheral, but not central, FGF1 increased islet beta-cell density, suggesting that peripheral FGF1 may induce long-term changes in islet structure and function that are not present with central treatment. |
